A new trading day began on Friday, with Avidity Biosciences Inc (NASDAQ: RNA) stock price up 0.92% from the previous day of trading, before settling in for the closing price of $32.63. RNA’s price has ranged from $11.23 to $56.00 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has jumped its sales by 58.16% annually for the last half of the decade. Meanwhile, its annual earnings per share averaged 1.40%. With a float of $108.26 million, this company’s outstanding shares have now reached $118.90 million.
In an organization with 253 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 80.79%, operating margin of -3209.35%, and the pretax margin is -2772.45%.
Avidity Biosciences Inc (RNA) Insider and Institutional Ownership
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Avidity Biosciences Inc is 9.26%, while institutional ownership is 101.15%. The most recent insider transaction that took place on Jan 21 ’25, was worth 53,537. In this transaction Director of this company sold 1,872 shares at a rate of $28.60, taking the stock ownership to the 12,958 shares. Before that another transaction happened on Jan 21 ’25, when Company’s Chief Financial Officer sold 3,287 for $28.59, making the entire transaction worth $93,985. This insider now owns 104,655 shares in total.
Avidity Biosciences Inc (RNA) Latest Financial update
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.77 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 1.40% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -7.10% during the next five years compared to -57.60% drop over the previous five years of trading.
Avidity Biosciences Inc (NASDAQ: RNA) Trading Performance Indicators
Here are Avidity Biosciences Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 17.76. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 388.23.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.90, a number that is poised to hit -0.79 in the next quarter and is forecasted to reach -3.30 in one year’s time.
Technical Analysis of Avidity Biosciences Inc (RNA)
Let’s dig in a bit further. During the last 5-days, its volume was 1.26 million. That was inferior than the volume of 1.32 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 84.42%. Additionally, its Average True Range was 1.86.
During the past 100 days, Avidity Biosciences Inc’s (RNA) raw stochastic average was set at 21.16%, which indicates a significant decrease from 86.63% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 48.92% in the past 14 days, which was lower than the 62.55% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $34.07, while its 200-day Moving Average is $37.93. However, in the short run, Avidity Biosciences Inc’s stock first resistance to watch stands at $33.73. Second resistance stands at $34.53. The third major resistance level sits at $35.17. If the price goes on to break the first support level at $32.28, it is likely to go to the next support level at $31.64. The third support level lies at $30.84 if the price breaches the second support level.
Avidity Biosciences Inc (NASDAQ: RNA) Key Stats
With a market capitalization of 3.93 billion, the company has a total of 119,309K Shares Outstanding. Currently, annual sales are 9,560 K while annual income is -212,220 K. The company’s previous quarter sales were 2,340 K while its latest quarter income was -80,400 K.
